| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | BCL7 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human BCL7A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于BCL7A抗体的相关文献概述：
1. **"BCL7A expression in diffuse large B-cell lymphoma: a potential biomarker for tumor progression"**
- 作者：Smith A, et al.
- 摘要：本研究利用BCL7A特异性抗体通过免疫组化分析DLBCL患者样本，发现BCL7A高表达与患者不良预后显著相关，提示其可能作为肿瘤进展的生物标志物。
2. **"Structural insights into BCL7A-containing SWI/SNF chromatin remodeling complexes"**
- 作者：Li Y, et al.
- 摘要：通过BCL7A抗体进行免疫共沉淀和质谱分析，揭示了BCL7A在SWI/SNF复合物中的结构作用，发现其通过调控染色质重塑影响基因转录。
3. **"BCL7A antibody validation for epigenetic studies in neurodevelopmental disorders"**
- 作者：Garcia R, et al.
- 摘要：验证了BCL7A抗体的特异性并应用于ChIP-seq实验，发现BCL7A在神经发育相关基因的表观遗传调控中起关键作用，尤其在自闭症模型中表达异常。
注：以上文献信息为模拟示例，实际引用需根据具体研究补充完整信息。
The BCL7A antibody targets the B-cell lymphoma 7 protein family member A (BCL7A), a component of the SWI/SNF chromatin-remodeling complex, specifically the BAF (BRG1/BRM-associated factor) subset. BCL7A plays a role in regulating gene expression by modifying chromatin structure, impacting cellular processes such as DNA repair, differentiation, and tumor suppression. Dysregulation of BCL7A has been linked to cancers, particularly B-cell malignancies like Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL), where chromosomal translocations or mutations may disrupt its function. Additionally, BCL7A is implicated in neurodevelopmental disorders, including Coffin-Lowry syndrome, when associated with SWI/SNF complex anomalies.
BCL7A antibodies are critical tools in research for detecting protein expression, localization, and interactions in both normal and pathological contexts. They are utilized in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to study BCL7A’s role in chromatin remodeling and its association with disease mechanisms. Validated antibodies help elucidate how BCL7A loss or mutation contributes to oncogenesis or developmental defects by altering transcriptional regulation. Researchers also explore its potential as a biomarker or therapeutic target, emphasizing its importance in understanding epigenetic dysregulation in cancer and genetic disorders. Proper antibody validation (e.g., knockout controls) ensures specificity, supporting reliable experimental outcomes in both basic and translational studies.
×
